London (ots/PRNewswire) - Accord Healthcare (Accord), one of Europe's fastest growing pharmaceutical companies, marks World Cancer Day 2023 today by taking part in news-style programme for ITN Business alongside other partners from industry and the patient community to raise awareness of the importance of working ...
Paris (ots/PRNewswire) - - A new ambition by 2030 to accelerate its transformation dynamic - A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal Servier today unveils its 2030 ambition as well as a new visual identity that reflects the transformation undertaken by the Group, bringing visible results. The Group intends to accelerate its transformation dynamics in order ...
Harrow, England (ots/PRNewswire) - Sondelbay – is a self-administered, once-a-day subcutaneous injection for patients with osteoporosis using a pen device - Accord's fourth biosimilar, joins the company's established portfolio across Europe, and marks its first branded product in a new Bone Health franchise representing another great milestone in Accord's growing ...
Fresenius Kabi Deutschland GmbH
Bad Homburg, Germany (ots/PRNewswire) - Real-world-data on the medical nutrition practice in Intensive Care Units (ICU) for critically ill patients is limited so far. To close this knowledge gap, Fresenius Kabi started EuroPN Study in 2019 in eleven European countries with around 100 participating hospitals[1]. At ...
Toronto (ots/PRNewswire) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or "Preparations") showed high efficacy in killing HER2+ breast ...
Prague (ots/PRNewswire) - Zentiva and mAbxience announce their collaboration for the launch of the ALYMSYS® (bevacizumab) following its European Marketing Authorisation on March 26th. The EC approval is based on a comprehensive clinical and scientific package which demonstrated biosimilarity of ALYMSYS® to the ...
Brussels (ots/PRNewswire) - · Revenue increased to EUR 5.3 billion (+9%, +8% CER[1]) net sales to EUR 5.1 billion (+8%, +7% CER) · Underlying profitability (adj. EBITDA[2]) was EUR 1.4 billion (+1%, -4% CER) or 27% of revenue · R&D update: bimekizumab filed with FDA and EMA for psoriasis; timelines for late stage pipeline confirmed - despite pandemic · Financial ...
Zurich (ots) - In 2019, medication costs in Switzerland totalled approximately CHF 7.6 billion. The front runners remained cancer and immune system drugs, followed by nervous system medications and metabolic preparations. The use of biosimilars (generic preparations) offers significant savings potential that unfortunately remains almost completely unexploited. In an ...
Brussels, Belgium (ots/PRNewswire) - - Underlines UCB's leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure - Staccato® Alprazolam could be a potential solution for ...
Zurich (ots) - The medication costs in Switzerland amounted to about CHF 7.6 billion in 2018. Since 2010, costs have risen by 46 percent, whereby half of this increase was attributable to immunosuppressants and cancer medication. Great savings potential is above all associated with the use of biosimilars. One of the other findings of this year's Helsana Drug Report is ...